Blog
RSS FeedPosted by Michael Wonder on 05 Apr 2023
Global blockbusters’ failure to win insurance coverage raises questions about fairness
5 April 2023 - Here is a case in which patients' treatment options and companies' business rights have been put ...
Posted by Michael Wonder on 04 Apr 2023
Long-waited drugs were approved, but patients must wait for insurance benefits
4 April 2023 - Braftovi (encorafenib) is a targeted agent used for VRAF V600E mutant metastatic colorectal cancer patients with ...
Posted by Michael Wonder on 28 Mar 2023
'To develop digital health, separate insurance coverage system needed’
28 March 2023 - The Government needs to establish a separate reimbursement registration frame for digital treatment devices that secure ...
Posted by Michael Wonder on 06 Mar 2023
Will reimbursement criteria of SMA treatment Spinraza change?
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen ...
Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...
Posted by Michael Wonder on 26 Jan 2023
New atopic dermatitis drugs for young patients to get expanded coverage
26 January 2023 - As the Government moves toward expanding insurance coverage for atopic dermatitis from adult to children and ...
Posted by Michael Wonder on 02 Jan 2023
Korea to exclude Australia from new drug pricing reference country list
30 December 2022 - HIRA has decided to leave Australia as a reference country when it sets drug prices next ...
Posted by Michael Wonder on 14 Dec 2022
HIRA sets up system to manage 'super-expensive' drugs
14 December 2022 - The Health Insurance Review and Assessment Service (HIRA) said it would operate a system to manage ...
Posted by Michael Wonder on 01 Dec 2022
Takeda Korea's Kynteles SC wins insurance benefit
1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...
Posted by Michael Wonder on 28 Nov 2022
'Reimbursement criteria for CGRP inhibiting migraine drugs not realistic'
28 November 2022 - The CGRP (calcitonin gene-related peptide) inhibitors, developed to prevent adult migraines, have recently been registered on ...
Posted by Michael Wonder on 27 Oct 2022
MSD's Zerbaxa becomes Korea's newest antibiotic to receive reimbursement
27 October 2022 - MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after ...
Posted by Michael Wonder on 12 Oct 2022
‘Current standard for stopping insurance benefits for SMA treatment harsh on adult patients’
12 October 2022 - Spinraza (nusinersen sodium), the first spinal muscular atrophy treatment that won the insurance coverage quickly since ...
Posted by Michael Wonder on 26 Sep 2022
Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails
22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the ...
Posted by Michael Wonder on 11 Sep 2022
Health movement in South Korea fights for universal access to medicines
10 September 2022 - Civil society in South Korea renewed its commitment to ensure universal access to medicines and public pharmaceutical ...
Posted by Michael Wonder on 01 Sep 2022
Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis
1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment ...